The FDA has approved Avastin™ (bevacizumab) in combination with chemotherapy as treatment for colorectal cancer that has progressed after initial treatment according to a news release from Genentech, Inc. on June 20, 2006.
Avastin™ was previously approved in February 2004 for first-line treatment in combination with 5FU-based chemotherapy.
Approval was based on results of a Phase III clinical trial conducted by the Eastern Oncology Cooperative Group that showed improved survival time when Avastin™ was added to FOLFOX4 chemotherapy. Patients receiving Avastin™ plus FOLFOX had a median survival of 12.4 months after beginning the second-line treatment compared to 10.7 months for patients on chemotherapy alone.
Leave a Reply
Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. FightCRC is not responsible for the medical accuracy of any comments left by persons other than FightCRC staff members. FightCRC staff members monitor comments and may respond publicly where appropriate.
Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.
We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment. For the best personal and direct response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).